Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia
Sílvia Xargay‐Torrent, Mònica López‐Guerra, Laia Rosich, et al.
Oncotarget (2015) Vol. 6, Iss. 26, pp. 22734-22749
Open Access | Times Cited: 66

Showing 26-50 of 66 citing articles:

Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins
Akihide Yoshimi, Omar Abdel‐Wahab
Clinical Cancer Research (2016) Vol. 23, Iss. 2, pp. 336-341
Open Access | Times Cited: 35
Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications
Andrea Pellagatti, Jacqueline Boultwood
Advances in Biological Regulation (2016) Vol. 63, pp. 59-70
Open Access | Times Cited: 34
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells
Mònica López‐Guerra, Sílvia Xargay‐Torrent, Patricia Fuentes, et al.
Oncogene (2019) Vol. 39, Iss. 6, pp. 1185-1197
Open Access | Times Cited: 30
Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets
Agata M. Bogusz, Adam Bagg
Leukemia & lymphoma/Leukemia and lymphoma (2016) Vol. 57, Iss. 9, pp. 1991-2013
Closed Access | Times Cited: 29
SF3B1mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
Irene López‐Oreja, André Gohr, Heribert Playà-Albinyana, et al.
Life Science Alliance (2023) Vol. 6, Iss. 11, pp. e202301955-e202301955
Open Access | Times Cited: 8
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
Arnau Montraveta, Eriong Lee‐Vergés, Jocabed Roldán, et al.
Oncotarget (2015) Vol. 7, Iss. 5, pp. 5507-5520
Open Access | Times Cited: 26
Sudemycin K: A Synthetic Antitumor Splicing Inhibitor Variant with Improved Activity and Versatile Chemistry
Kamil Makowski, Luisa Vigevani, Fernando Alberício, et al.
ACS Chemical Biology (2016) Vol. 12, Iss. 1, pp. 163-173
Open Access | Times Cited: 25
Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression
Bing Han, Yihang Shen, Piyan Zhang, et al.
Oncotarget (2017) Vol. 8, Iss. 14, pp. 22490-22500
Open Access | Times Cited: 25
Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target
Rocco Sciarrillo, Francesca Terrana, Annalisa Comandatore, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 8, pp. 3173-3184
Open Access | Times Cited: 2
Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
Richard N. Armstrong, Violetta Steeples, Shalini Singh, et al.
Advances in Biological Regulation (2017) Vol. 67, pp. 13-29
Open Access | Times Cited: 23
Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
Charlotte Brierley, David P. Steensma
Current Hematologic Malignancy Reports (2016) Vol. 11, Iss. 6, pp. 408-415
Closed Access | Times Cited: 20
Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines
Joana Jorge, Sara Petronilho, Raquel Alves, et al.
Investigational New Drugs (2019) Vol. 38, Iss. 2, pp. 369-377
Closed Access | Times Cited: 20
Splicing dysregulation in human hematologic malignancies: beyond splicing mutations
Jonas De Kesel, Igor Fijałkowski, Justin Taylor, et al.
Trends in Immunology (2022) Vol. 43, Iss. 8, pp. 674-686
Open Access | Times Cited: 11
RNA splicing, cell signaling, and response to therapies
Chérine Abou Fayçal, Sylvie Gazzéri, Béatrice Eymin
Current Opinion in Oncology (2015) Vol. 28, Iss. 1, pp. 58-64
Open Access | Times Cited: 20
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
Viralkumar Patel, Michael J. Keating, William G. Wierda, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2015) Vol. 57, Iss. 6, pp. 1494-1497
Open Access | Times Cited: 19
Key Molecular Drivers of Chronic Lymphocytic Leukemia
Suliman A. Alsagaby, Paul Brennan, Chris Pepper
Clinical Lymphoma Myeloma & Leukemia (2016) Vol. 16, Iss. 11, pp. 593-606
Closed Access | Times Cited: 18
Therapeutic approaches to treat human spliceosomal diseases
Anthony B. DeNicola, Yi Tang
Current Opinion in Biotechnology (2019) Vol. 60, pp. 72-81
Open Access | Times Cited: 18
An exon skipping screen identifies antitumor drugs that are potent modulators of pre-mRNA splicing, suggesting new therapeutic applications
Yihui Shi, Walter M. Bray, Alexander J. Smith, et al.
PLoS ONE (2020) Vol. 15, Iss. 5, pp. e0233672-e0233672
Open Access | Times Cited: 17
Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data
Huayu Wu, Zhigang Peng, Rong‐Quan He, et al.
International Journal of Oncology (2019)
Open Access | Times Cited: 17
Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency
George B. Kyei, Shanshan Meng, Rashmi Ramani, et al.
mBio (2018) Vol. 9, Iss. 6
Open Access | Times Cited: 16
Chemotherapy induces alternative transcription and splicing: Facts and hopes for cancer treatment
Charles Lambert, Nancy Garbacki, Alain Colige
The International Journal of Biochemistry & Cell Biology (2017) Vol. 91, pp. 84-97
Closed Access | Times Cited: 15
Chronic lymphocytic leukaemia genomics and the precision medicine era
Hussein Ghamlouch, Florence Nguyen‐Khac, Olivier Bernard
British Journal of Haematology (2017) Vol. 178, Iss. 6, pp. 852-870
Open Access | Times Cited: 15
Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations—NOTCH1, SF3B1, MYD88, BIRC3
Maciej Putowski, Krzysztof Giannopoulos
Journal of Clinical Medicine (2021) Vol. 10, Iss. 16, pp. 3735-3735
Open Access | Times Cited: 11
An intricate rewiring of cancer metabolism via alternative splicing
Gazmend Temaj, Silvia Chichiarelli, Sarmistha Saha, et al.
Biochemical Pharmacology (2023) Vol. 217, pp. 115848-115848
Closed Access | Times Cited: 4
Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression
Mark Sellin, Ryan Mack, Matthew C. Rhodes, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 2, pp. 223-236
Open Access | Times Cited: 6

Scroll to top